Metagen Therapeutics Raises ¥200M Series B for Microbiome-Based Drug Discovery

Metagen Therapeutics Secures ¥200M Series B

Metagen Therapeutics, a biotechnology company focused on drug discovery and development based on intestinal microbiome-based therapeutics, has raised ¥200 million in Series B funding. The round was announced on September 4, 2026.

What Metagen Therapeutics Does

Metagen Therapeutics operates in the biotechnology sector, with a focus on discovering and developing drugs based on the intestinal microbiome. The company's work centres on translating microbiome science into therapeutic candidates.

Microbiome-based therapeutics is an emerging area of drug development that explores how the composition and function of gut bacteria can be leveraged to treat disease. Metagen Therapeutics is positioned within this field, pursuing drug discovery and development programmes grounded in intestinal microbiome research.

Funding Details

• Round type: Series B
• Amount raised: ¥200,000,000 JPY
• Announcement date: September 4, 2026
• Lead investor: Not disclosed
• Investors: Hokkaido University Green Frontier Fund No.1, Tokai Research and Development No.1

The Series B includes participation from Hokkaido University Green Frontier Fund No.1 and Tokai Research and Development No.1. No lead investor was named in the available information.

Investor Context

The involvement of Hokkaido University Green Frontier Fund No.1 and Tokai Research and Development No.1 suggests a connection to academic and regional research and development ecosystems. University-affiliated and regional R&D funds often support early- and growth-stage biotechnology companies that are commercialising research from academic institutions or regional innovation clusters.

For Metagen Therapeutics, this backing may provide not only capital but also access to research networks and development resources associated with these investors.

Why This Matters for the Biotech Ecosystem

Microbiome-based drug discovery has attracted growing interest as researchers uncover links between gut bacteria and a range of health conditions. Companies in this space typically require significant capital for preclinical and clinical development, making Series B rounds an important milestone as they advance programmes toward later-stage trials.

The ¥200 million round provides Metagen Therapeutics with funding to continue its drug discovery and development efforts. The participation of university-linked and R&D-focused investors aligns with the company's research-intensive profile.

Acquisition Perspective

For acquirers and strategic partners in biotechnology and pharmaceuticals, Metagen Therapeutics represents a specialist player in the intestinal microbiome therapeutics field. Companies with proprietary discovery platforms and development pipelines in emerging therapeutic areas can be attractive targets for larger biopharma firms seeking to expand their research portfolios or enter new modalities.

At Series B stage, Metagen Therapeutics is likely focused on advancing its pipeline and validating its approach. The involvement of academic and regional R&D funds may also signal a strong research foundation, which can be relevant to potential partners evaluating the scientific basis of the company's programmes.

Summary

Metagen Therapeutics has raised ¥200 million in Series B funding, announced on September 4, 2026. The biotechnology company focuses on drug discovery and development based on intestinal microbiome-based therapeutics. Investors in the round include Hokkaido University Green Frontier Fund No.1 and Tokai Research and Development No.1. No lead investor was disclosed.